Promaxo, a medical imaging, robotics, and AI technology company based in Oakland, California, reported strong first-quarter 2023 results. The company sold fourteen systems during the quarter ending March 31, 2023, representing growth from eight systems sold in Q4 2022. These sales were distributed across physician practices, ambulatory surgery centers, and integrated delivery networks.
The company expanded its geographic footprint by entering five new states: Colorado, Kentucky, Nebraska, Nevada, and Wisconsin. Since launching commercially in Q4 2021, Promaxo has sold 40 systems across sixteen states total.
CEO Dr. Amit Vohra noted the quarter “demonstrated strong execution,” highlighting January sales momentum and “increased traction, adoption, and expansion across our target markets.” The company emphasized growing usage among early adopters and continued focus on market penetration.
Promaxo’s FDA-cleared single-sided MRI system with AI-based imaging guides prostate interventions in office-based settings. The company, backed by over 200 patents, aims to improve diagnosis and intervention quality through compact, adaptable MRI technology.